In the phase III RUBY clinical trial, the Jemperli regimen showed a statistically significant and clinically meaningful improvement in progression free survival in the mismatch repair deficient/microsatellite instability-high population and in the overall population.
Chemotherapy is known to cause behavioral side effects, including cognitive decline. Notably, the gut microbiome communicates with the brain to affect behavior, including cognition.
